Haddadin Yezan Munther

Average Profitability
52.96%
Insider Buys Quantity
6
Insider Buys Sum
$111,772.30
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Haddadin Yezan Munther

According to the SEC Form 4 filings, Haddadin Yezan Munther, being in a position of

  1. director at Outlook Therapeutics, Inc.,
    оver the last 12 months, has bought 1882 shares for $22,242, and sold 0 shares,
    over all time since 2020-09-22, has bought 75225 shares for $111,772, and sold 0 shares.

The largest purchase of all time was on 2022-10-06 and amounted to 29743 shares of Outlook Therapeutics, Inc. for $38,368.

Biography of Haddadin Yezan Munther

No biography is available at this moment.

2024-03-28PurchaseOutlook Therapeutics, Inc.
OTLK
director
1,881.71
0.0143%
$11.82$22,242-37.92%
2022-10-07PurchaseOutlook Therapeutics, Inc.
OTLK
director
3,600
0.0016%
$1.27$4,572-9.92%
2022-10-06PurchaseOutlook Therapeutics, Inc.
OTLK
director
29,743
0.0134%
$1.29$38,368-9.52%
2021-12-02PurchaseOutlook Therapeutics, Inc.
OTLK
director
10,000
0.0054%
$1.39$13,900-9.42%
2021-04-19PurchaseOutlook Therapeutics, Inc.
OTLK
director
10,000
0.0059%
$1.82$18,200+14.21%
2020-09-22PurchaseOutlook Therapeutics, Inc.
OTLK
director
20,000
0.0232%
$0.72$14,490+217.09%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.